Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VRC-FLUDNA082-00-VP
- Development stage
- Unknown
- Lead developer
- Vaccine Research Center
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VRC-FLUDNA082-00-VP is an investigational DNA plasmid vaccine developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID). It is designed to elicit an immune response against the H2N2 subtype of the Influenza A virus. The vaccine contains a DNA plasmid encoding the hemagglutinin (HA) protein from the A/Singapore/1/1957 (H2N2) strain. In clinical development, it has been evaluated in prime-boost regimens, often serving as the priming agent followed by a boost with a ferritin-based nanoparticle vaccine (such as VRC-FLUNPF081-00-VP) to induce broader and more potent neutralizing antibody responses against H2 influenza viruses.
- Other names
- H2N2 influenza DNA vaccineH-2N2 influenza DNA vaccineH 2N2 influenza DNA vaccineA/Singapore/1/1957 HA DNA vaccine
02
Targets
HA (Influenza A virus hemagglutinin (A/Singapore/1/1957))
Beyond the preview
Go deeper on VRC-FLUDNA082-00-VP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VRC-FLUDNA082-00-VP.